A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer.

Background Based on the convenient oral dosing of erlotinib and the promising results of biologic therapy, we undertook a phase II study with 21 patients with locally advanced (T3–4) lesions combining radiation with intra-arterial (IA) cisplatin and oral daily erlotinib for a 7-week therapy.